Moderna (MRNA) Shares Soar 4.54% on FDA Vaccine Approval for Children

Moderna (MRNA) shares surged 4.54% today, marking the third consecutive day of gains, with a cumulative increase of 14.65% over the past three days. The stock price reached its highest level since March 2025, with an intraday gain of 4.88%.

The strategy of buying MRNA shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 7.5% annualized return. The maximum drawdown during this period was 34.8%, which occurred in early 2023, following a peak in November 2021. The strategy's Sharpe ratio was 0.65, indicating good risk-adjusted returns. However, there was significant volatility, with a standard deviation of 28.1%. Overall, this strategy provided decent returns with reasonable risk management, making it suitable for investors seeking a balanced approach..

One of the most significant factors driving Moderna's recent stock performance is the FDA's full approval of the company's COVID-19 vaccine, Spikevax (mRNA-1273), for children aged 6 months through 11 years who are at increased risk for COVID-19. This approval, announced on July 10, 2025, expands the vaccine's reach and underscores its importance for vulnerable children, potentially influencing investors' perceptions and the company's market performance.

This approval is a major milestone for Moderna, as it allows the company to market its vaccine to a broader demographic, including young children who are at higher risk of severe COVID-19 complications. The expanded approval is expected to boost demand for the vaccine and potentially increase Moderna's revenue streams. Investors are likely to view this development positively, as it demonstrates the company's ability to adapt and innovate in response to evolving public health needs.

Additionally, the approval highlights Moderna's leadership in mRNA vaccine technology, which has been a key driver of the company's success during the pandemic. The company's ability to develop and deploy effective vaccines quickly has positioned it as a leader in the biotechnology sector, and this latest approval is likely to further solidify its market position. As Moderna continues to expand its vaccine portfolio and explore new applications for its mRNA technology, investors are likely to remain optimistic about the company's long-term prospects.